Literature DB >> 19909502

Long-term gas exchange characteristics as markers of deterioration in patients with cystic fibrosis.

Richard Kraemer1, Philipp Latzin, Isabelle Pramana, Pietro Ballinari, Sabina Gallati, Urs Frey.   

Abstract

BACKGROUND AND AIM: In patients with cystic fibrosis (CF) the architecture of the developing lungs and the ventilation of lung units are progressively affected, influencing intrapulmonary gas mixing and gas exchange. We examined the long-term course of blood gas measurements in relation to characteristics of lung function and the influence of different CFTR genotype upon this process.
METHODS: Serial annual measurements of PaO2 and PaCO2 assessed in relation to lung function, providing functional residual capacity (FRCpleth), lung clearance index (LCI), trapped gas (VTG), airway resistance (sReff), and forced expiratory indices (FEV1, FEF50), were collected in 178 children (88 males; 90 females) with CF, over an age range of 5 to 18 years. Linear mixed model analysis and binary logistic regression analysis were used to define predominant lung function parameters influencing oxygenation and carbon dioxide elimination.
RESULTS: PaO2 decreased linearly from age 5 to 18 years, and was mainly associated with FRCpleth, (p < 0.0001), FEV1 (p < 0.001), FEF50 (p < 0.002), and LCI (p < 0.002), indicating that oxygenation was associated with the degree of pulmonary hyperinflation, ventilation inhomogeneities and impeded airway function. PaCO2 showed a transitory phase of low PaCO2 values, mainly during the age range of 5 to 12 years. Both PaO2 and PaCO2 presented with different progression slopes within specific CFTR genotypes.
CONCLUSION: In the long-term evaluation of gas exchange characteristics, an association with different lung function patterns was found and was closely related to specific genotypes. Early examination of blood gases may reveal hypocarbia, presumably reflecting compensatory mechanisms to improve oxygenation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19909502      PMCID: PMC2780404          DOI: 10.1186/1465-9921-10-106

Source DB:  PubMed          Journal:  Respir Res        ISSN: 1465-9921


  43 in total

1.  Survival patterns in cyctic fibrosis.

Authors:  W J Warwick; R E Pogue; H U Gerber; C J Nesbitt
Journal:  J Chronic Dis       Date:  1975-12

2.  Early detection of pulmonary function abnormalities in cystic fibrosis.

Authors:  A Lamarre; B J Reilly; A C Bryan; H Levison
Journal:  Pediatrics       Date:  1972-08       Impact factor: 7.124

3.  Ear lobe blood samples for blood gas analysis at rest and during exercise.

Authors:  S Godfrey; E R Wozniak; R J Courtenay Evans; C S Samuels
Journal:  Br J Dis Chest       Date:  1971-01

4.  Evaluation of ventilation maldistribution as an early indicator of lung disease in children with cystic fibrosis.

Authors:  P M Gustafsson; P Aurora; A Lindblad
Journal:  Eur Respir J       Date:  2003-12       Impact factor: 16.671

5.  The role of common single-nucleotide polymorphisms on exon 9 and exon 12 skipping in nonmutated CFTR alleles.

Authors:  Bernhard Steiner; Kaspar Truninger; Javier Sanz; André Schaller; Sabina Gallati
Journal:  Hum Mutat       Date:  2004-08       Impact factor: 4.878

6.  Hypoxemia in attack free asthmatic children: relationship with lung volumes and lung mechanics.

Authors:  B Wolf; C Gaultier; C Lopez; M Boulé; F Girard
Journal:  Bull Eur Physiopathol Respir       Date:  1983 Sep-Oct

7.  Setting of noninvasive pressure support in young patients with cystic fibrosis.

Authors:  B Fauroux; F Nicot; S Essouri; N Hart; A Clément; M I Polkey; F Lofaso
Journal:  Eur Respir J       Date:  2004-10       Impact factor: 16.671

8.  Use of capillary blood in measurement of arterial PO2.

Authors:  J MacIntyre; J N Norman; G Smith
Journal:  Br Med J       Date:  1968-09-14

9.  Determination of capillary oxygen tension in infants and children: assessment of methodology and normal values during growth.

Authors:  C Gaultier; M Boulé; Y Allaire; A Clément; A Buvry; F Girard
Journal:  Bull Eur Physiopathol Respir       Date:  1979 May-Jun

10.  The CFTR frameshift mutation 3905insT and its effect at transcript and protein level.

Authors:  Javier Sanz; Thomas von Känel; Mircea Schneider; Bernhard Steiner; André Schaller; Sabina Gallati
Journal:  Eur J Hum Genet       Date:  2009-09-02       Impact factor: 4.246

View more
  5 in total

1.  Identification of SNPs in the cystic fibrosis interactome influencing pulmonary progression in cystic fibrosis.

Authors:  Franziska M Gisler; Thomas von Kanel; Richard Kraemer; André Schaller; Sabina Gallati
Journal:  Eur J Hum Genet       Date:  2012-08-15       Impact factor: 4.246

2.  Nocturnal non invasive ventilation in normocapnic cystic fibrosis patients: a pilot study.

Authors:  Maria Papale; Giuseppe Parisi; Lucia Spicuzza; Novella Rotolo; Enza Mulè; Donatella Aloisio; Sara Manti; Salvatore Leonardi
Journal:  Acta Biomed       Date:  2021-05-12

3.  Naja naja atra venom ameliorates pulmonary fibrosis by inhibiting inflammatory response and oxidative stress.

Authors:  Kui Cui; Jian-Qun Kou; Jin-Hua Gu; Rong Han; Guanghui Wang; Xuechu Zhen; Zheng-Hong Qin
Journal:  BMC Complement Altern Med       Date:  2014-12-02       Impact factor: 3.659

4.  Diagnostic accuracy of methacholine challenge tests assessing airway hyperreactivity in asthmatic patients - a multifunctional approach.

Authors:  Richard Kraemer; Hans-Jürgen Smith; Thomas Sigrist; Gabi Giger; Roland Keller; Martin Frey
Journal:  Respir Res       Date:  2016-11-17

Review 5.  Disease-modifying genes and monogenic disorders: experience in cystic fibrosis.

Authors:  Sabina Gallati
Journal:  Appl Clin Genet       Date:  2014-07-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.